Hollow Mesoporous\nPrussian Blue Nanoparticles\nLoaded with Daunorubicin for Acute\nMyeloid Leukemia Treatment

Abstract

The most effective treatment for acute myeloid leukemia\n relies\non high-dose chemotherapeutic agents. However, this therapy is prone\nto serious adverse effects due to the lack of targeted selectivity.\nThe CXC chemokine receptor 4 (CXCR4) overexpressed on the surface\nof acute myeloid leukemia cells is closely associated with poor prognosis\nand is an important clinical target. In this study, we report the\nconstruction of a biomimetic nanomedicine with targeted effects based\non the CXCR4/CXC chemokine ligand 12 (CXCL12) biological axis by coating\nbone marrow stromal cell membranes (CMs) on the surface of hollow\nmesoporous Prussian blue nanoparticles (HMPB NPs) loaded with daunorubicin\n(DNR), namely, HMPB(DNR)@CM NPs, which inherit the CXCL12 of mouse\nbone marrow stromal (MS-5) cells. Due to the inherent CXCL12, HMPB(DNR)@CM\nNPs exhibit prominent advantages in targeted delivery, which enhances\nthe killing of acute myeloid leukemia cells, and the migration and\nadhesion of acute myeloid leukemia cells to MS-5 cells are inhibited\nafter treatment with nanocarriers. These CMs biomimicry also endows\nthe nanocarrier with immune evasion as a property. More importantly,\nPB nanocarriers with reactive oxygen species scavenging activity and\nslow drug release can effectively alleviate the damage caused by chemotherapeutic\ndrugs to hepatocytes. As a result of this research, the construction\nof safer and more effective chemotherapy strategies is expected to\nbe facilitated, and the prognosis of acute myeloid leukemia patients\nis expected to be improved.